Rapidly progressive IgA nephropathy: A form of vasculitis or a complement-mediated disease?

Clinical Kidney Journal

Volumn 8, Issue 5, 2015, Pages 477-481

  Rojas Rivera, Jorge ^a   Fernández Juárez, Gema ^b   Praga, Manuel ^c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

ANCA; Complement activation; Crescentic glomerulonephritis; IgA nephropathy

Indexed keywords

COMPLEMENT; ECULIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; COMPLEMENT DISORDER; COMPLEMENT SYSTEM; DISEASE COURSE; END STAGE RENAL DISEASE; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; VASCULITIS;

EID: 84954064829     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv095     Document Type: Review

References (39)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;245:709-727
2. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455-1458
3. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005;16:2088-2097
4. Barratt J. Immunopathogenesis of IgAN. Semin Immunopathol 2007;29:427-443
5. Mestecky J, Tomana M, Moldoveanu Z et al. Role of aberrant glycosilation of IgA1 in the pathogenesis of IgA nephropathy. Kidney Blood Pres Res 2008;31:29-37
6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012;2(Suppl):139-274
7. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathy. J Nephrol 2005;18:503-512
8. Gutiérrez E, Zamora I, Ballarin JA et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23:1753-1760
9. Gutiérrez E, González E, Hernández E et al. Factors that determine an incomplete recovery or renal function in macrohematuriainduced acute renal failure in IgA nephropathy. Clin J Am Soc Nephrol 2007;2:51-57
10. Martin-Cleary C, Moreno JA, Fernández B et al. Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant 2010;25:4103-4106
11. Rocatello D, Ferro M, Coppo R et al. Treatment of rapidly progressive IgA nephropathy. In: Clarkson A, Woodroffe A (eds). IgA Nephropathy: Pathogenesis and Treatment. Basel: Karger, 1995, vol. 111, pp. 177-1483
12. Habib R, Niaudet P, Levy M. Schonlein-Henoch purpura nephritis and IgAnephropathy. In: Tisher C, Brenner BM (eds). Renal Pathology: with Clinical and Pathological Correlations, 2nd edn. Philadelphia, PA: Lippincott, 1994, pp. 472-523
13. Habib R, Jennette JC. Immunoglobulin A nephropathy and Henoch-Schonlein purpura. In: Fogo AB, Bruijn JA, Cohen AH, Colvin RB, Jennette JC (eds). Fundamentals of Renal Pathology. New York: Springer, 2006, pp. 61-69
14. Haas M, Jafri J, Bartosh SM et al. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 2000;36:709-718
15. Bantis C, Stangou M, Schlaugat C et al. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dise 2010;55:259-268
16. Huang X, Wang Y, Xie L et al. IgA nephropathy with antineutrophil cytoplasmic antibody seropositivity. Clin Nephrol 2015;84:156-164
17. Philibert D, Cattran D, Cook T. Clinicopathologic correlations in IgA nephropathy. Semin Nephrol 2008;28:10-17
18. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011;43:321-327
19. Kiryluk K, Li Y, Scolari F et al. Discovery of newrisk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014;46:1187-1196
20. Zhu L, Zhai Y-L, Wang F-M et al. Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol 2015;26:1195-1204
21. Oortwijn BD, Eijgenraam JW, Rastaldi MP et al. The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol 2008;28:58-65
22. Espinoza M, Ortega R, Sánchez M et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014;9:897-904
23. Gherghiceanu M, Penescu M, Mandache E. The predictive value of peritubular capillaries C3d deposition in IgA glomerulonephritis. J Cell Mol Med 2005;9:143-152
24. Komatsu H, Fujimoto S, Hara S et al. Relationship between serum IgA/C3 ratio and the progression of IgA nephropathy. Intern Med 2004;43:1023-1028
25. Nakayama K, Ohsawa I, Maeda-Ohtani A et al. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal 2008;22:114-119
26. Moreno JA, Marin-Cleary C, Gutiérrez E et al. AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 2012;7:175-184
27. Frimat M, Tabarin F, Dimitrov JD et al. Complement activation by heme as secondary hit for atypical hemolytic uremic syndrome. Blood 2013;122:282-292
28. Yang Y-z, Shi S-F, Chen Y-Q et al. Clinical features of IgA nephropathy with serum ANCA-positivity: a retrospective case-control study. Clin Kidney J 2015;8:482-488
29. Lv J, Yang Y, Zhang H et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol 2013;24:2118-2125
30. Hilhorst M, van Paasen P, Tervaert JW. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol 2015; doi: 10.3109/08916934.2015.1027815
31. Terrier B, Saadoun D, Sène D et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009;68:1564-1571
32. Ring T, Pedersen BB, Salkus G et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015;8:489-491
33. Rousset-Rouviere C, Cailliez M, Garaix F et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014;29:1107-1111
34. Coppo R, Peruzzi L, Amore A et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-172
35. Jayne DRW, Bruchfeld A, Schaier M et al. Phase 2 randomised trial of oral C5a receptor antagonist CCX168 in ANCAassociated renal vasculitis. Nephrol Dial Transplant 2014;29(Suppl 3):iii 27-29
36. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357-1366
37. De Vriese AS, Sethi S, van Praet J et al. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2015020184
38. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009;29:282-291
39. Bu F, Meyer NC, Zhang Y et al. Soluble C5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 2015;65:968-969